{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:08:15Z","timestamp":1789006095141,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Data on bictegravir\/emtricitabine\/tenofovir\u00a0alafenamide\u00a0(B\/F\/TAF)\u00a0in people with both HIV-1 and HBV are limited, particularly for treatment-experienced people.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ALLIANCE was a randomized, double-blind, active-controlled, phase 3 study of B\/F\/TAF versus dolutegravir (DTG)\u2009+\u2009emtricitabine\/tenofovir disoproxil fumarate (F\/TDF) in treatment-na\u00efve adults with HIV-1 RNA\u2009\u2265\u2009500 copies\/mL and HBV DNA\u2009\u2265\u20092000\u00a0IU\/mL. Participants received continuous B\/F\/TAF through 144\u00a0weeks (\u2265\u200996\u00a0weeks of blinded treatment plus 48-week optional open-label extension [OLE]) or switched to B\/F\/TAF after\u2009\u2265\u200996\u00a0weeks of DTG\u2009+\u2009F\/TDF through 48\u00a0weeks of OLE. Here we report outcomes from the OLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>121 participants were included in the continuous B\/F\/TAF group; 89 in the switch group. Median B\/F\/TAF exposure was 186.4 and 48\u00a0weeks, respectively. HIV-1 and HBV suppression rates (missing\u2009=\u2009excluded) were maintained in both groups (B\/F\/TAF Week 144: 99.0% and 80.2%; switch OLE Week 48: 95.4% and 86.6%, respectively). Both groups had improved alanine aminotransferase normalization. HBV envelope antigen loss and seroconversion occurred in 44.8% and 29.3%, respectively, of participants receiving continuous B\/F\/TAF (Week 144) and 17.0% and 12.8% in the switch group (OLE Week 48). HBV surface antigen loss and seroconversion occurred in 22.5% and 15.5% (continuous B\/F\/TAF), and 4.3% and 0% (switch group) of participants, respectively. One participant (continuous B\/F\/TAF) discontinued due to study drug\u2013unrelated treatment-emergent adverse event. No treatment-emergent resistance was reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>B\/F\/TAF was effective in HIV-1 and HBV suppression and well tolerated in treatment-na\u00efve individuals for\u2009\u2264\u20093\u00a0years and\u2009\u2264\u20091\u00a0year after switching from a TDF-based regimen.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      ClinicalTrials.gov NCT03547908 (first registration 2018-05-24).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12981-026-00891-4","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:04:38Z","timestamp":1784185478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["B\/F\/TAF in people with both HIV-1 and hepatitis B: outcomes from the ALLIANCE open-label extension phase"],"prefix":"10.1186","volume":"23","clinical-trial-number":[{"clinical-trial-number":"nct03547908","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Anchalee","family":"Avihingsanon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Loon","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasisopin","family":"Kiertiburanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Po","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"D\u2019Antoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharline","family":"Madera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-3423","authenticated-orcid":false,"given":"Jason T.","family":"Hindman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"891_CR1","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/cid\/ciz1170","volume":"71","author":"S Leumi","year":"2020","unstructured":"Leumi S, Bigna JJ, Amougou MA, Ngouo A, Nyaga UF, Noubiap JJ. Global burden of hepatitis B infection in people living with human immunodeficiency virus: a systematic review and meta-analysis. Clin Infect Dis. 2020;71:2799\u2013806.","journal-title":"Clin Infect Dis"},{"key":"891_CR2","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1097\/QAD.0000000000001646","volume":"31","author":"AC Thornton","year":"2017","unstructured":"Thornton AC, Jose S, Bhagani S, Chadwick D, Dunn D, Gilson R, et al. Hepatitis B, hepatitis C, and mortality among HIV-positive individuals. AIDS. 2017;31:2525\u201332.","journal-title":"AIDS"},{"key":"891_CR3","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1097\/QAD.0000000000001574","volume":"31","author":"KP Singh","year":"2017","unstructured":"Singh KP, Crane M, Audsley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS. 2017;31:2035\u201352.","journal-title":"AIDS"},{"key":"891_CR4","first-page":"14","volume":"31","author":"MA Corcorran","year":"2023","unstructured":"Corcorran MA, Kim N. Chronic hepatitis B and HIV coinfection. Top Antivir Med. 2023;31:14\u201322.","journal-title":"Top Antivir Med"},{"key":"891_CR5","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/cid\/cix122","volume":"64","author":"MJ Vinikoor","year":"2017","unstructured":"Vinikoor MJ, Sinkala E, Chilengi R, Mulenga LB, Chi BH, Zyambo Z, et al. Impact of antiretroviral therapy on liver fibrosis among human immunodeficiency virus-infected adults with and without HBV coinfection in Zambia. Clin Infect Dis. 2017;64:1343\u20139.","journal-title":"Clin Infect Dis"},{"key":"891_CR6","unstructured":"Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2025. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf. Accessed 10 Feb 2025."},{"key":"891_CR7","unstructured":"European AIDS Clinical Society. EACS Guidelines v13.0. 2025. https:\/\/eacs.sanfordguide.com\/. Accessed 8 Apr 2026."},{"key":"891_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jama.2024.24543","volume":"333","author":"RT Gandhi","year":"2025","unstructured":"Gandhi RT, Landovitz RJ, Sax PE, Smith DM, Springer SA, G\u00fcnthard HF, et al. Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society\u2013USA panel. JAMA. 2025;333:609\u201328.","journal-title":"JAMA"},{"key":"891_CR9","doi-asserted-by":"publisher","first-page":"e29899","DOI":"10.1002\/jmv.29899","volume":"96","author":"K Andreatta","year":"2024","unstructured":"Andreatta K, D\u2019Antoni ML, Chang S, Parvangada A, Martin R, Blair C, et al. High efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence. J Med Virol. 2024;96:e29899.","journal-title":"J Med Virol"},{"key":"891_CR10","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1093\/jac\/dkz347","volume":"74","author":"K Andreatta","year":"2019","unstructured":"Andreatta K, Willkom M, Martin R, Chang S, Wei L, Liu H, et al. Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I. J Antimicrob Chemother. 2019;74:3555\u201364.","journal-title":"J Antimicrob Chemother"},{"key":"891_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/hiv.13593","volume":"25","author":"S Esser","year":"2024","unstructured":"Esser S, Brunetta J, Inciarte A, Levy I, D\u2019Arminio Monforte A, Lambert JS, et al. Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV: real-world insights from BICSTaR cohorts. HIV Med. 2024;25:440\u201353.","journal-title":"HIV Med"},{"key":"891_CR12","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390:2063\u201372.","journal-title":"Lancet"},{"key":"891_CR13","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","volume":"7","author":"C Orkin","year":"2020","unstructured":"Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020;7:e389\u2013400.","journal-title":"Lancet HIV"},{"key":"891_CR14","doi-asserted-by":"publisher","first-page":"101991","DOI":"10.1016\/j.eclinm.2023.101991","volume":"59","author":"PE Sax","year":"2023","unstructured":"Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E. Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. eClinicalMedicine. 2023;59:101991.","journal-title":"eClinicalMedicine"},{"key":"891_CR15","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","volume":"6","author":"HJ Stellbrink","year":"2019","unstructured":"Stellbrink HJ, Arribas JR, Stephens JL, Albrecht H, Sax PE, Maggiolo F, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamideversus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6:e364\u201372.","journal-title":"Lancet HIV"},{"key":"891_CR16","doi-asserted-by":"publisher","first-page":"2456890","DOI":"10.1080\/25787489.2025.2456890","volume":"26","author":"B Trottier","year":"2025","unstructured":"Trottier B, Yang CJ, Watanabe D, Marchetti G, Elbirt D, De Barra E, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort. HIV Res Clin Pract. 2025;26:2456890.","journal-title":"HIV Res Clin Pract"},{"key":"891_CR17","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","volume":"6","author":"DA Wohl","year":"2019","unstructured":"Wohl DA, Yazdanpanah Y, Baumgarten A, Clarke A, Thompson MA, Brinson C, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6:e355\u201363.","journal-title":"Lancet HIV"},{"key":"891_CR18","doi-asserted-by":"publisher","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","volume":"10","author":"A Avihingsanon","year":"2023","unstructured":"Avihingsanon A, Lu H, Leong CL, Hung CC, Koenig E, Kiertiburanakul S, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. Lancet HIV. 2023;10:e640\u201352.","journal-title":"Lancet HIV"},{"key":"891_CR19","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"key":"891_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, Chan HLY, Chuang W-L, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196\u2013206.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"891_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","volume":"119","author":"HLY Chan","year":"2024","unstructured":"Chan HLY, Buti M, Lim YS, Agarwal K, Marcellin P, Brunetto M, et al. Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety. Am J Gastroenterol. 2024;119:486\u201396.","journal-title":"Am J Gastroenterol"},{"key":"891_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HLY Chan","year":"2016","unstructured":"Chan HLY, Fung S, Seto WK, Chuang W-L, Chen C-Y, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185\u201395.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"891_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/apt.17107","volume":"56","author":"E Ogawa","year":"2022","unstructured":"Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, et al. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. Aliment Pharmacol Ther. 2022;56:713\u201322.","journal-title":"Aliment Pharmacol Ther"},{"key":"891_CR24","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/QAD.0000000000003865","volume":"38","author":"C Orkin","year":"2024","unstructured":"Orkin C, Antinori A, Rockstroh JK, Moreno-Guillen S, Martorell CT, Molina JM, et al. Switch to bictegravir\/emtricitabine\/tenofovir alafenamide from dolutegravir-based therapy. AIDS. 2024;38:983\u201391.","journal-title":"AIDS"},{"key":"891_CR25","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/apt.18278","volume":"60","author":"M Buti","year":"2024","unstructured":"Buti M, Lim YS, Chan HLY, Agarwal K, Marcellin P, Brunetto MR, et al. Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: final results from two randomised phase 3 trials. Aliment Pharmacol Ther. 2024;60:1573\u201386.","journal-title":"Aliment Pharmacol Ther"},{"key":"891_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","volume":"5","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020;5:441\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"891_CR27","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/apt.16788","volume":"55","author":"YS Lim","year":"2022","unstructured":"Lim YS, Seto WK, Kurosaki M, Fung S, Kao JH, Hou J, et al. Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. Aliment Pharmacol Ther. 2022;55:921\u201343.","journal-title":"Aliment Pharmacol Ther"},{"key":"891_CR28","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1002\/hep.22883","volume":"49","author":"CL Thio","year":"2009","unstructured":"Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009;49:S138\u201345.","journal-title":"Hepatology"},{"key":"891_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","volume":"4","author":"K Zhou","year":"2019","unstructured":"Zhou K, Contag C, Whitaker E, Terrault N. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. Lancet Gastroenterol Hepatol. 2019;4:227\u201338.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"891_CR30","doi-asserted-by":"publisher","first-page":"ofab621","DOI":"10.1093\/ofid\/ofab621","volume":"9","author":"PWG Mallon","year":"2022","unstructured":"Mallon PWG, Brunet L, Fusco JS, Prajapati G, Beyer A, Fusco GP, et al. Lipid changes after switch from TDF to TAF in the OPERA cohort: LDL cholesterol and triglycerides. Open Forum Infect Dis. 2022;9:ofab621.","journal-title":"Open Forum Infect Dis"},{"key":"891_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","volume":"63","author":"PJ Ruane","year":"2013","unstructured":"Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, et al. Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63:449\u201355.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"891_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","volume":"396","author":"KH Mayer","year":"2020","unstructured":"Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396:239\u201354.","journal-title":"Lancet"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-026-00891-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-026-00891-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-026-00891-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:26:34Z","timestamp":1789003594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12981-026-00891-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1186\/s12981-026-00891-4","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants provided written informed consent. The study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by independent review boards and ethics committees.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have read the journal's policy on disclosure of competing interests, and the following interests are declared: AA has received research\/grant support from Gilead Sciences, Inc., GSK\/ViiV Healthcare, MSD, and Roche; travel support from Gilead Sciences, Inc.; and serves as a member of the Committee of Thai AIDS Society; the Strategic and Technical Advisory Group on HIV, Hepatitis and STI for WHO SEARO; and the Thailand National Committee on ART, Hepatitis and TB\/TPT. C\u2013CH has received research\/grant support, consulting fees, and speaker honoraria from Gilead Sciences, Inc. MLD, SM, HW, and JTH are employees of, and own stocks\/shares in, Gilead Sciences, Inc. TL has received support for the present study from Gilead Sciences, Inc.; speaker honoraria from Gilead Sciences, Inc., GSK Pharmaceuticals, and Perkin Elmer; travel support from Gilead Sciences, Inc., GSK Pharmaceuticals, and Sansure Biotech; and is the Chair of the Chinese Society of Infectious Diseases. CLL, SK, and M-PL declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"85"}}